P14.66 TTFields dose distribution and tumor growth patterns confirm clinical activity of TTFields: MRI analysis of the randomized phase 3 EF-14 trial

BACKGROUND: The randomized phase 3 EF-14 trial showed that the addition of tumor treating fields (TTFields) to temozolomide (TMZ) treatment improved survival in newly diagnosed glioblastoma patients over TMZ alone. As TTFields delivery is designed to optimize dose at the tumor bed, we hypothesized t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Kebir, S, Ballo, M T, Jeyapalan, S, Toms, S A, Hottinger, A, Pollom, E, Glas, M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Poster Presentations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795946/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.301
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars